Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL<sup>+</sup> human leukemia".
Where this comes from
- Record sourced from PubMed, PMID 31316004.
- Also identified by DOI 10.1126/scitranslmed.aav0819.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
LB100 sensitizes resistant chronic phase CML stem and progenitor cells to TKIs and spares healthy bone marrow cells.
Medical subject headings
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive